March 8th 2024
Your daily dose of the clinical news you may have missed.
March 1st 2024
Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.
February 5th 2024
December 22nd 2023
Common triggers, such as stress, travel, and disrupted routines, can impact patients with migraine this holiday season. Practical strategies and short-term preventive measures to help, here.
November 30th 2023
Which antihypertensive therapy options are most and least effective for patients with migraine? Get details, here.
The Most Effective Medications for Acute Migraines: Patient Perspectives
Which medications are most effective for acute migraine management? A recent study assessed which ones appeared to work best based on reported patient experience.
Migraine in Pregnancy & Lactation: Considerations for Treatment
Get details on which migraine treatments are the better option for women who are breastfeeding, and on ones to advise them to avoid.
Migraine in Pregnancy: Considerations for Treatment
An overview of safe treatment options for migraine attacks that may occur during pregnancy for primary care clinicians, here.
Novel Neurostimulation Device Shows Significant Benefit for Migraine
The device from Nexalin Technology outperformed placebo on key measures of pain relief, sleep quality, anxiety, and quality of life.
Primary Care Management of Headache: Part 2
An overview of oral preventive medication options for migraine for primary care clinicians, here.
Daily Dose: Atogepant Associated with Reduction in Monthly Migraine Days
A daily dose of clinical news on Patient Care you may have missed.
Atogepant Reduces Monthly Migraine Days vs Placebo in Persons with Chronic Migraine
The oral gepant reduced monthly migraine days as well as mean monthly use of migraine rescue medication.
7 New Approved Drugs for Primary Care: Q2 2023
The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?
Primary Care Management of Headache: Part 1
An overview of common headache conditions and treatments for primary care clinicians, here.
Menstrual Migraine: Common and Disabling
Menstrual migraine is often described as more disabling than non-menstrual migraine. Get an overview and test your knowledge, here.
Daily Dose: Migraine without Aura Raises Stroke Risk for Women on Combined Hormonal Contraceptives
Your daily dose of clinical news you may have missed.
Migraine without Aura May Increase Stroke Risk for Women Taking Combined Hormonal Contraceptives
The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.
Where Does Migraine Pain Come From?
The role of the trigeminal nerve and its connection to the brainstem has led to a greater understanding of where migraine pain originates. Expert explains, here.
Atogepant Granted Label Expansion for Prevention of Chronic Migraine
The oral calcitonin gene-related peptide receptor antagonist is now indicated for prevention in both episodic and chronic migraine.
FDA Approves Novel Formulation of Rizatriptan Benzoate for Acute Migraine Treatment
To be marketed as Rizafilm, the product is a disintegrating film formulation of the 5-HT-1 receptor antagonist and proven bioequivalent to Merck's Maxalt-MLT.
FDA Approves First Intranasal CGRP Receptor Antagonist for Adult Migraine
Zavegepant, the first FDA-approved intranasal CGRP receptor antagonist, could be available in pharmacies by July 2023.
Nerivio Prescription Wearable Cleared by FDA for Preventive Treatment of Migraine
The prescription remote electrical neuromodulation device is now cleared for both acute and preventive treatment of migraine in those aged ≥12 years, according to Theranica.
Zavegepant Intranasal Migraine Agent Meets Coprimary Endpoints in Phase 3 Trial, Pfizer Announces
Pain relief from the intranasally-delivered calcitonin gene-related peptide antagonist began as soon as 15 minutes post-dose and for some patients lasted up to 48 hours.
Daily Dose: Migraine and Pregnancy Complications
Eptinezumab Significantly Reduced Patient-reported Migraine Impact on HRQoL in Medication Overuse Headache and Chronic Migraine
Study participants with medication overuse headache reported quality of life improvements as early as study week 4 that were sustained at week 24.
Migraine History May Be a Risk Factor for Pregnancy Complications: New Findings
Among women with prepregnancy migraine diagnosis, rates of gestational hypertension and preeclampsia were 28% and 40% higher, respectively, vs women without migraine.
Remote Electrical Neuromodulation Device Effective for Migraine Prevention in Pivotal Trial
The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.
Migraine with Aura Characterized as Independent Risk Factor for Atrial Fibrillation
Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.
Gepant sNDA for Chronic Migraine: Atogepant from AbbVie
If the atogepant label is expanded, the drug will be the only gepant approved for the broad indication of prevention of both episodic and chronic migraine.
Rimegepant for Acute Migraine May Reduce Use of, Reliance on Opioids: New Data
Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.
Potential IBS-Migraine Association Seen in Nationwide Survey
Individuals with migraine were found more likely to have IBS and IBS was more prevalent in those with migraine; both associations were statistically significant.
Atogepant: Pivotal Phase 3 Study Meets Primary Endpoint for Preventive Treatment of Chronic Migraine
Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.
10 Questions on Migraine Impact, Diagnosis, & Treatment Based on the OVERCOME Study
Lifetime use of opioids for migraine was found to be higher than for triptan medications. Try these 10 questions on other OVERCOME findings.
Unmet Needs in US Migraine Headache Management: OVERCOME Study First Data
Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.
Largest Genetic Study of Migraine to Date Identifies New Risk Factors
Researchers identified over 120 regions connected to risk of migraine, of which 86 were previously unknown.